David M. Brown, MD

Associate Professor of Clinical Ophthalmology, Academic Institute
Associate Clinical Member, Research Institute
Houston Methodist
Weill Cornell Medical College


After completing his postdoctoral training, Dr. Brown joined the faculty at the Baylor College of Medicine as a Clinical Instructor in the Department of Ophthalmology. He received his faculty appointment at the Weill Medical College in 2006.

Description of Research

Dr. Brown’s research centers on clinical investigations to evaluate treatments for diabetic retinopathy, neovascular age-related macular degeneration, central retinal vein occlusion, and retinal detachment. Dr. Brown was a key investigator on the Anti-VEGF Antibody for the Treatment of Predominantly Classic Choroidal Neovascularization in Age-related Macular Degeneration (ANCHOR) Study and the Minimally classic/occult trial of the anti-VEGF antibody ranibizumab in the treatment of neovascular AMD (MARINA) Study which both demonstrated a statistically significant benefit of Lucentis (ranibizumab) over Visudyne (verteporfin photodynamic therapy [PDT]) in predominantly classic choroidal neovascularization (CNV). Dr. Brown is also a member of the Diabetic Retinopathy Clinical Research Network.

Areas Of Expertise

Diabetic retinopathy Neovascular age-related macular degeneration Central retinal vein occlusion Retinal detachment
Education & Training

MD, Baylor College of Medicine
Internship, Baylor College of Medicine
Residency, University of Iowa Hospitals and Clinics

Wykoff, CC, Avery, RL, Barakat, MR, Boyer, DS, Brown, DM, Brucker, AJ, Cunningham, ET, Heier, JS, Holekamp, NM, Kaiser, PK, Khanani, AM, Kim, JE, Demirci, H, Regillo, CD, Yiu, GC & Ciulla, TA 2024, , Retina, vol. 44, no. 6, pp. 939-949. https://doi.org/10.1097/IAE.0000000000004087

Intravitreal aflibercept 8 mg in diabetic macular oedema (PHOTON): 48-week results from a randomised, double-masked, non-inferiority, phase 2/3 trial
PHOTON Investigators 2024, , The Lancet, vol. 403, no. 10432, pp. 1153-1163. https://doi.org/10.1016/S0140-6736(23)02577-1

Faricimab Treat-and-Extend for Diabetic Macular Edema: Two-Year Results from the Randomized Phase 3 YOSEMITE and RHINE Trials
YOSEMITE and RHINE Investigators 2024, , Ophthalmology, vol. 131, no. 6, pp. 708-723. https://doi.org/10.1016/j.ophtha.2023.12.026

TENAYA and LUCERNE: Two-Year Results from the Phase 3 Neovascular Age-Related Macular Degeneration Trials of Faricimab with Treat-and-Extend Dosing in Year 2
TENAYA and LUCERNE Investigators 2024, , Ophthalmology. https://doi.org/10.1016/j.ophtha.2024.02.014

Gene therapy for neovascular age-related macular degeneration by subretinal delivery of RGX-314: a phase 1/2a dose-escalation study
Campochiaro, PA, Avery, R, Brown, DM, Heier, JS, Ho, AC, Huddleston, SM, Jaffe, GJ, Khanani, AM, Pakola, S, Pieramici, DJ, Wykoff, CC & Van Everen, S 2024, , The Lancet, vol. 403, no. 10436, pp. 1563-1573. https://doi.org/10.1016/S0140-6736(24)00310-6

Pegcetacoplan for the treatment of geographic atrophy secondary to age-related macular degeneration (OAKS and DERBY): two multicentre, randomised, double-masked, sham-controlled, phase 3 trials
OAKS and DERBY 2023, , The Lancet, vol. 402, no. 10411, pp. 1434-1448. https://doi.org/10.1016/S0140-6736(23)01520-9

Effect of High-Dose Intravitreal Aflibercept, 8 mg, in Patients With Neovascular Age-Related Macular Degeneration: The Phase 2 CANDELA Randomized Clinical Trial
CANDELA Study Investigators 2023, , JAMA Ophthalmology, vol. 141, no. 9, pp. 834-842. https://doi.org/10.1001/jamaophthalmol.2023.2421

Risk Factors for the Development of Fellow Eye Horseshoe Retinal Tears Following Horseshoe Retinal Tear in the Presenting Eye
Peng, ET, Parvus, MN, Yu, HJ, Laswell, SM, Pearce, WA, Fan, KC, Major, JC, Brown, DM, Wykoff, CC & Patel, SB 2023, , Ophthalmic Surgery Lasers and Imaging Retina, vol. 54, no. 6, pp. 338-345. https://doi.org/10.3928/23258160-20230523-01

Demographic and Socioeconomic Factors in Prospective Retina-Focused Clinical Trial Screening and Enrollment
Cao, JA, Patel, SB, Wong, CW, Garcia, D, Munoz, J, Cone, C, Zamora, D, Reagan, M, Nguyen, TV, Pearce, W, Fish, RH, Brown, DM, Chaudhary, V, Wykoff, CC & Fan, KC 2023, , Journal of Personalized Medicine, vol. 13, no. 6, 880. https://doi.org/10.3390/jpm13060880

Rao, AV, Shah, AR, Nguyen, VT, Pearce, W, Wong, TP, Brown, DM, Wykoff, CC & Patel, SB 2023, , Retina, vol. 43, no. 5, pp. 802-807. https://doi.org/10.1097/IAE.0000000000003718

Efficacy, durability, and safety of faricimab with extended dosing up to every 16 weeks in Japanese patients with diabetic macular edema: 1-year results from the Japan subgroup of the phase 3 YOSEMITE trial
on behalf of the YOSEMITE and RHINE Investigators 2023, , Japanese Journal of Ophthalmology, vol. 67, no. 3, pp. 264-279. https://doi.org/10.1007/s10384-023-00979-8

Impact of retinal fluid-free months on outcomes in neovascular age-related macular degeneration: A treatment agnostic analysis of the hawk and harrier studies
Eichenbaum, D, Brown, DM, Ip, M, Khanani, AM, Figueroa, MS, McAllister, IL, Laude, A, Uruprasad, B, Tang, S, Gmeiner, B, Clemens, A & Souied, E 2023, , Retina, vol. 43, no. 4, pp. 632-640. https://doi.org/10.1097/IAE.0000000000003699

A Randomized Controlled Trial of OPT-302, a VEGF-C/D Inhibitor for Neovascular Age-Related Macular Degeneration
Opthea Study Group Investigators 2023, , Ophthalmology, vol. 130, no. 6, pp. 588-597. https://doi.org/10.1016/j.ophtha.2023.02.001

HAWK Extension Study: Safety and Efficacy of Intravitreal Brolucizumab in Neovascular Age-related Macular Degeneration
on behalf of the HAWK Extension Study Investigators 2023, , Current Eye Research, vol. 48, no. 1, pp. 44-50. https://doi.org/10.1080/02713683.2022.2096907

Prediction for 2-Year Vision Outcomes Using Early Morphologic and Functional Responses in the Comparison of Age-related Macular Degeneration Treatments Trials
Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group 2023, , Ophthalmology Retina, vol. 7, no. 7, pp. 564-572. https://doi.org/10.1016/j.oret.2023.02.008

Intravitreal Nesvacumab (Anti-Angiopoietin-2) Plus Aflibercept in Neovascular AMD: Phase 2 ONYX Randomized Trial
Heier, JS, Ho, AC, Boyer, DS, Csaky, K, Vitti, R, Perlee, L, Chu, KW, Asmus, F, Leal, S, Zeitz, O, Cheng, Y, Schmelter, T & Brown, DM 2023, , Journal of VitreoRetinal Diseases, vol. 7, no. 1, pp. 8-15. https://doi.org/10.1177/24741264221126061

Fan, W, Fleming, A, Hemert, JV, Wykoff, CC, Brown, DM, Robertson, G, Wang, K, Falavarjani, KG, Sadda, SR & Ip, M 2022, , Retina, vol. 42, no. 10, pp. 1883-1888. https://doi.org/10.1097/IAE.0000000000003549

MERLIN: Phase 3a, Multicenter, Randomized, Double-Masked Trial of Brolucizumab in Participants with Neovascular Age-Related Macular Degeneration and Persistent Retinal Fluid
MERLIN Investigators 2022, , Ophthalmology, vol. 129, no. 9, pp. 974-985. https://doi.org/10.1016/j.ophtha.2022.04.028

Final Outcomes from the Randomized RECOVERY Trial of Aflibercept for Retinal Nonperfusion in Proliferative Diabetic Retinopathy
RECOVERY Study Group 2022, , Ophthalmology Retina, vol. 6, no. 7, pp. 557-566. https://doi.org/10.1016/j.oret.2022.02.013

KESTREL and KITE: 52-Week Results From Two Phase III Pivotal Trials of Brolucizumab for Diabetic Macular Edema
Brown, DM, Emanuelli, A, Bandello, F, Barranco, JJE, Figueira, J, Souied, E, Wolf, S, Gupta, V, Ngah, NF, Liew, G, Tuli, R, Tadayoni, R, Dhoot, D, Wang, L, Bouillaud, E, Wang, Y, Kovacic, L, Guerard, N & Garweg, JG 2022, , American Journal of Ophthalmology, vol. 238, pp. 157-172. https://doi.org/10.1016/j.ajo.2022.01.004